SCHEMBL2829058

SCHEMBL2829058

O=C(Oc1ccccn1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
METAP1 P53582 2/20 0.53
METAP2 P50579 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
NPC1 O15118 3/20 0.49
PKM P14618 2/20 0.49
RAB9A P51151 2/20 0.49
MITF O75030 1/20 0.49
CDK5 Q00535 1/20 0.49
CDK5R1 Q15078 1/20 0.49
KMT2A Q03164 6/20 0.48
F2 P00734 1/20 0.48
MAPT P10636 7/20 0.47
KDM4E B2RXH2 4/20 0.47
KDM6B O15054 1/20 0.47
KDM4A O75164 1/20 0.47
KDM5C P41229 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM2A Q9Y2K7 1/20 0.47
KDM3A Q9Y4C1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30532884 1.00 LMNA (0.53) LMNAMETAP1METAP2HDAC6NPC1
Hydrochloric Acid SCHEMBL21811038 0.98 LMNA (0.51) LMNAMETAP1METAP2HDAC6NPC1
SCHEMBL28420765 0.94 MAPT (0.49) LMNAMETAP1METAP2HDAC6NPC1
SCHEMBL28438069 0.89 HSD17B10 (0.56) LMNAMETAP1METAP2HDAC6NPC1
SCHEMBL1603559 0.87 ESR1 (0.45) LMNAMETAP1METAP2HDAC6NPC1
Hydrochloric Acid SCHEMBL27395418 0.87 HSD17B10 (0.55) LMNAMETAP1METAP2HDAC6NPC1
SCHEMBL28446167 0.87 KDM4E (0.55) LMNAMETAP1METAP2HDAC6KMT2A
SCHEMBL31337903 0.86 MAPT (0.52) LMNAMETAP1METAP2HDAC6NPC1
SCHEMBL31337908 0.86 NPC1 (0.54) LMNANPC1PKMRAB9AKMT2A
SCHEMBL31337907 0.86 NPC1 (0.56) NPC1PKMRAB9ACDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955262-A Direct cross-coupling method of pyridine ester and aryl bromide 南京工业大学 2024-11-15 CN claimed
EP-2168578-B1 Thiazole based inhibitors of ATP-utilizing enzymes GENENTECH INC (US) 2012-12-19 EP claimed
EP-2168578-A2 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof Genentech, Inc. (US) 2010-03-31 EP claimed
US-20090048313-A1 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF GENENTECH, INC. (US) 2009-02-19 US claimed
EP-1781287-A4 THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES GENENTECH INC (US) 2008-02-27 EP claimed
CN-101048158-A Thiazole based inhibitors of ATP-utilizing enyzmes GENENTECH INC (US) 2007-10-03 CN claimed
EP-1781287-A2 THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES Genentech, Inc. (US) 2007-05-09 EP claimed
US-20060052416-A1 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof SQUARE 1 BANK 2006-03-09 US claimed
WO-2006020767-A2 THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENZYMES GENENTECH, INC. (US) 2006-02-23 WO claimed
EP-1309590-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2003-05-14 EP claimed
WO-2001098299-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2001-12-27 WO claimed
CN-118955262-A Direct cross-coupling method of pyridine ester and aryl bromide 南京工业大学 2024-11-15 CN disclosed
WO-2024046457-A1 TRIAZINE COMPOUNDS AND USES THEREOF HUTCHMED LIMITED (CN) 2024-03-07 WO disclosed
WO-2023169569-A1 TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2023-09-14 WO disclosed
CN-116731016-A Tricyclic heterocyclic compounds as IAP antagonists 苏州亚盛药业有限公司 2023-09-12 CN disclosed
CN-1088927-A Benzo and pyrido pyridazinone and pyridazinthione compounds SYNTEX A INC (US) 1994-07-06 CN disclosed
US-5250517-A Hypotensive and cardiotonic agents; cardiac insufficiency HOFFMANN-LA ROCHE INC. (US) 1993-10-05 US disclosed
EP-0467721-A1 Optically active compound having a delta- valerolactone ring and liquid crystal composition containing same MITSUBISHI RAYON CO., LTD (JP) 1992-01-22 EP disclosed
US-4020073-A Process for O-acylating thallus salts of 2-pyridone TAYLOR EDWARD C 1977-04-26 US disclosed
US-3947488-A O-Acylation using organothallium compounds TAYLOR EDWARD C 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048313-A1 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF ATP5ME, ATP5MG, ATP5MK LMNA 4104/4885METAP1 701/4885METAP2 456/4885
US-20060052416-A1 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK LMNA 4104/4885METAP1 701/4885METAP2 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.